Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous vs intravenous isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
CTR20223208Phase 3Active
- Sponsor
- Sanofi
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by Sanofi. Primary endpoints: Overall response rate (ORR) and Isatuximab pre-dose trough concentration (Ctrough) at steady state. Started Feb 2023; status: active.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20223208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223208.